AbbVie Reports Third-Quarter 2024 Financial Results

ABBV 10.30.2024

SERA-AI Powered Highlights
Drug:UNKNOWN-UNKNOWN Humira
Drug:UNKNOWN-UNKNOWN Skyrizi
Drug:UNKNOWN-UNKNOWN Rinvoq
Drug:UNKNOWN-UNKNOWN Imbruvica
Drug:UNKNOWN-UNKNOWN Venclexta
Drug:UNKNOWN-UNKNOWN Botox Therapeutic
Drug:UNKNOWN-UNKNOWN Vraylar
Drug:UNKNOWN-UNKNOWN Ubrelvy
Drug:UNKNOWN-UNKNOWN Qulipta
Drug:UNKNOWN-UNKNOWN Botox Cosmetic
Drug:UNKNOWN-UNKNOWN Juvederm
Diseases:ulcerative colitis
Diseases:Parkinson's disease
Diseases:follicular lymphoma
Diseases:nonsquamous non-small cell lung cancer
Diseases:platinum-resistant ovarian cancer
Full Press ReleaseSEC FilingsOur ABBV Tweets

About Gravity Analytica

Recent News

  • 01.31.2025 - AbbVie to Host Fourth Quarter 2024 Earnings Conference Call
  • 01.15.2025 - J.P. Morgan Healthcare Conference
  • 01.03.2025 - AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.06.2025 - EX-99.1 EX-99.1
  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • Reports Third-Quarter Diluted EPS of$0.88on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of$3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of$0.04Per Share Related to Acquired IPR&D and Milestones Expense
  • Delivers Third-Quarter Net Revenues of$14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis
  • Third-Quarter Global Net Revenues from the Immunology Portfolio Were$7.046 Billion, an Increase of 3.9 Percent on a Reported Basis, or 4.8 Percent on an Operational Basis; Global Humira Net Revenues Were$2.227 Billion; Global Skyrizi Net Revenues Were$3.205 Billion; Global Rinvoq Net Revenues Were$1.614 Billion
  • Third-Quarter Global Net Revenues from the Oncology Portfolio Were$1.687 Billion, an Increase of 11.6 Percent on a Reported Basis, or 13.0 Percent on an Operational Basis; Global Imbruvica Net Revenues Were$828 Million; Global Venclexta Net Revenues Were$677 Million
  • Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were$2.363 Billion, an Increase of 15.6 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were$848 Million; Global Vraylar Net Revenues Were$875 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were$445 Million
  • Third-Quarter Global Net Revenues from the Aesthetics Portfolio Were$1.239 Billion, a Decrease of 0.1 Percent on a Reported Basis, or an Increase of 1.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were$671 Million; Global Juvederm Net Revenues Were$258 Million
  • Successfully Completed Acquisition of Cerevel, Adding Pipeline of Highly Complementary Assets toAbbVie's Existing Neuroscience Portfolio
  • Raises 2024Adjusted Diluted EPS Guidance Rangefrom$10.67-$10.87to$10.90-$10.94, which Includes an Unfavorable Impact of$0.64Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2024
  • Announces 2025 Dividend Increase of 5.8 Percent, Beginning with Dividend Payable inFebruary 2025

NORTH CHICAGO, Ill.,Oct. 30, 2024/PRNewswire/ --AbbVie(NYSE:ABBV) announced financial results for the third quarter endedSeptember 30, 2024.

"We delivered another quarter of strong commercial execution and significant pipeline progress," saidRobert A. Michael, chief executive officer,AbbVie. "Based upon the momentum ofAbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend."

Third-Quarter Results

  • Worldwide net revenues were$14.460 billion, an increase of 3.8 percent on a reported basis, or 4.9 percent on an operational basis.
  • Global net revenues from the immunology portfolio were$7.046 billion, an increase of 3.9 percent on a reported basis, or 4.8 percent on an operational basis.
    • Global Humira net revenues of$2.227 billiondecreased 37.2 percent on a reported basis, or 36.5 percent on an operational basis.U.S.Humira net revenues were$1.765 billion, a decrease of 41.6 percent. Internationally, Humira net revenues were$462 million, a decrease of 12.4 percent on a reported basis, or 7.8 percent on an operational basis.
    • Global Skyrizi net revenues were$3.205 billion, an increase of 50.8 percent on a reported basis, or 51.5 percent on an operational basis.
    • Global Rinvoq net revenues were$1.614 billion, an increase of 45.3 percent on a reported basis, or 47.4 percent on an operational basis.
  • Global net revenues from the oncology portfolio were$1.687 billion, an increase of 11.6 percent on a reported basis, or 13.0 percent on an operational basis.
    • Global Imbruvica net revenues were$828 million, a decrease of 8.8 percent, withU.S.net revenues of$618 millionand international profit sharing of$210 million.
    • Global Venclexta net revenues were$677 million, an increase of 14.8 percent on a reported basis, or 18.2 percent on an operational basis.
    • Global Elahere net revenues were$139 million.
  • Global net revenues from the neuroscience portfolio were$2.363 billion, an increase of 15.6 percent on a reported basis, or 16.0 percent on an operational basis.
    • Global Botox Therapeutic net revenues were$848 million, an increase of 13.4 percent on a reported basis, or 14.4 percent on an operational basis.
    • Global Vraylar net revenues were$875 million, an increase of 16.6 percent.
    • Global Ubrelvy net revenues were$269 million, an increase of 15.3 percent.
    • Global Qulipta net revenues were$176 million, an increase of 33.6 percent.
  • Global net revenues from the aesthetics portfolio were$1.239 billion, a decrease of 0.1 percent on a reported basis, or an increase of 1.8 percent on an operational basis.
    • Global Botox Cosmetic net revenues were$671 million, an increase of 8.2 percent on a reported basis, or 9.9 percent on an operational basis.
    • Global Juvederm net revenues were$258 million, a decrease of 19.7 percent on a reported basis, or 16.9 percent on an operational basis.
  • On a GAAP basis, the gross margin ratio in the third quarter was 70.9 percent. The adjusted gross margin ratio was 84.4 percent.
  • On a GAAP basis, selling, general and administrative (SG&A) expense was 29.1 percent of net revenues. The adjusted SG&A expense was 23.0 percent of net revenues.
  • On a GAAP basis, research and development (R&D) expense was 14.7 percent of net revenues. The adjusted R&D expense was 14.2 percent of net revenues.
  • Acquired IPR&D and milestones expense was 0.6 percent of net revenues.
  • On a GAAP basis, the operating margin in the third quarter was 26.5 percent. The adjusted operating margin was 46.7 percent.
  • Net interest expense was$591 million.
  • On a GAAP basis, the tax rate in the quarter was 25.0 percent. The adjusted tax rate was 16.2 percent.
  • Diluted EPS in the third quarter was$0.88on a GAAP basis. Adjusted diluted EPS, excluding specified items, was$3.00. These results include an unfavorable impact of$0.04per share related to acquired IPR&D and milestones expense.

Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

Recent Events

  • AbbVieannounced that it completed its acquisition of Cerevel, adding a pipeline of highly complementary assets toAbbVie's existing neuroscience portfolio. Cerevel's pipeline includes emraclidine, a potential best-in-class, next-generation antipsychotic, that is being studied for the treatment of schizophrenia; tavapadon, a first-in-class dopamine D1/D5 selective partial agonist for the management of Parkinson's disease (PD); as well as CVL-354, a potential best-in-class kappa opioid receptor (KOR) antagonist being studied for the treatment of major depressive disorder (MDD). Cerevel is a strong strategic fit forAbbVieand has potential to meaningfully impact revenue into the next decade.
  • AbbVieannounced positive topline results from its pivotal Phase 3 TEMPO-1 trial evaluating tavapadon as a fixed-dose monotherapy treatment in early PD. In the study, tavapadon met the primary endpoint, demonstrating a statistically significant improvement from baseline in theMovement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26. Tavapadon also met the key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II score. Full results from the TEMPO-1 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for PD. Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
  • AbbVieannounced theU.S. Food and Drug Administration(FDA) approved Vyalev (foscarbidopa and foslevodopa) as the first subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced PD. The approval was supported by results from a pivotal Phase 3 head-to-head, randomized and controlled clinical trial that demonstrated a statistically significant improvement in "on" time without troublesome dyskinesia and decreased "off" time, compared to oral immediate-release carbidopa/levodopa (CD/LD).
  • AbbVieand Aliada Therapeutics announced a definitive agreement under whichAbbViewill acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer's disease (AD). The acquisition also allowsAbbVieto utilize Aliada's novel BBB-crossing technology to enhance discovery and development efforts across neuroscience.
  • AbbVieandGedeon Richterannounced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboration expands upon the success of nearly two decades of partnership on CNS projects.
  • AbbVieannounced theEuropean Commission(EC) approved Skyrizi (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to conventional or biologic therapy. The approval was supported by data from two pivotal Phase 3 trials in which Skyrizi achieved the primary endpoint of clinical remission as well as key secondary endpoints. This marketing authorization for Skyrizi marks its fourth approved indication in theEuropean Union(EU). Skyrizi is part of a collaboration betweenBoehringer IngelheimandAbbVie, withAbbVieleading development and commercialization globally.
  • At theEuropean Academy of DermatologyandVenerology (EADV) Congress2024,AbbVieshared more than 30 presentations that showcased the depth and strength ofAbbVie's dermatology portfolio. Presentations highlighted data for Rinvoq (upadacitinib), Skyrizi and lutikizumab across a multitude of dermatological conditions.
  • AbbVieannounced that the EC granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of prior therapy. Tepkinly is the first subcutaneous bispecific antibody conditionally approved as a monotherapy in the EU to treat both r/r FL and r/r diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy.The ECapproval is supported by data from the Phase 1/2 EPCORE NHL-1 clinical trial, which evaluated the safety and efficacy of Tepkinly in adult patients with r/r FL. Tepkinly is being co-developed byAbbVieand Genmab.
  • AbbVieannounced theEuropean Medicines Agency's(EMA)Committee for Medicinal Productsfor Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior treatment regimens. The CHMP's opinion is supported by results of the Phase 3 MIRASOL clinical trial and the EC decision on this indication for Elahere is anticipated later this year.
  • AbbVieannounced submission of a Biologics License Application (BLA) to the FDA for accelerated approval (AA) of Teliso-V (telisotuzumab vedotin) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression. The BLA is supported by data from the Phase 2 LUMINOSITY clinical trial and review of the BLA will be conducted underFDA'sOncology Center of Excellence (OCE) Real-Time Oncology Review(RTOR) program. There are currently no approved anti-cancer therapies specifically for c-Met overexpressing NSCLC and if approved, Teliso-V would be the first-in-class therapy for this patient population.
  • At theEuropean Society for Medical Oncology (ESMO) Congress2024,AbbVieshowcased new data from its innovative antibody-drug conjugate (ADC) platform in tumor types with high unmet needs. Highlights included full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating Elahere for high FRα expressing platinum-sensitive ovarian cancer (PSOC); patient reported outcomes from the Phase 2 LUMINOSITY trial, evaluating Teliso-V in advanced NSCLC; as well as new safety and efficacy data in pre-treated patients with advanced NSCLC and gastroesophageal (GEA) cancer, from a Phase 1 study of ABBV-400 (telisotuzumab adizutecan).
  • Allergan Aesthetics announced the FDA approved Botox Cosmetic (onabotulinumtoxinA) for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults. Botox Cosmetic is the first product with four aesthetic indication areas: forehead lines, frown lines, crow's feet lines, and now platysma bands, making it the first product of its kind to go beyond the face.
  • Allergan Aesthetics announced the launch of Botox Cosmetic for the treatment of masseter muscle prominence (MMP) inChina. The approval is supported by Botox Cosmetic's well-established safety profile as well as clinical trial data that demonstrated Botox Cosmetic is effective in reducing the prominence of the masseter muscle. Botox Cosmetic is the first neurotoxin approved inChinafor MMP, the largest global MMP market. Allergan Aesthetics intends to develop Botox Cosmetic treatment for MMP in additional global markets and expand the use of Botox Cosmetic in the lower face.
  • At theAmerican Society for Dermal Surgery(ASDS), Allergan Aesthetics presented a total of 12 abstracts that showcased its commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments. Highlights included four Best of Cosmetic Abstracts as well as a panel discussion on the impact of social media on patient experience and expectations when considering aesthetic treatment.

Full-Year 2024 Outlook

AbbVieis raising its adjusted diluted EPS guidance for the full year 2024 from$10.67-$10.87to$10.90-$10.94, which includes an unfavorable impact of$0.64per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted. Any potential IPR&D and milestones expense related to the recently announced acquisition of Aliada Therapeutics is also excluded fromAbbVie's 2024 adjusted diluted EPS guidance, as the transaction is expected to close in the fourth quarter of 2024.

Company Declares Dividend Increase of 5.8 Percent

AbbVieis announcing today that its board of directors declared an increase in the company's quarterly cash dividend from$1.55per share to$1.64per share beginning with the dividend payable onFebruary 14, 2025to shareholders of record as ofJanuary 15, 2025. This reflects an increase of approximately 5.8 percent, continuingAbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013,AbbViehas increased its quarterly dividend by 310 percent.AbbVieis a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

AboutAbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience and eye care - and products and services across our Allergan Aesthetics portfolio. For more information aboutAbbVie, please visit us atwww.abbvie.com. Follow@abbvieon X (formerly Twitter),Facebook,Instagram,YouTubeorLinkedIn.

Conference Call

AbbViewill host an investor conference call today at8:00 a.m. Central Timeto discuss our third-quarter performance. The call will be webcast throughAbbVie's Investor Relations website atinvestors.abbvie.com. An archived edition of the call will be available after11:00 a.m. Central Time.

Non-GAAP Financial Results

Financial results for 2024 and 2023 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release.AbbVie's management believes non-GAAP financial measures provide useful information to investors regardingAbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.AbbViecautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affectAbbVie's operations is set forth in Item 1A, "Risk Factors," ofAbbVie's 2023 Annual Report on Form 10-K, which has been filed with theSecurities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents thatAbbViesubsequently files with theSecurities and Exchange Commissionthat update, supplement or supersede such information.AbbVieundertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

AbbVie Inc.

Key Product Revenues

Quarter EndedSeptember 30, 2024

(Unaudited)

% Change vs. 3Q23

Net Revenues (in millions)

Reported

Operationala

U.S.

Int'l.

Total

U.S.

Int'l.

Total

Int'l.

Total

NET REVENUES

$11,148

$3,312

$14,460

2.7 %

7.7 %

3.8 %

12.4 %

4.9 %

Immunology

5,713

1,333

7,046

0.3

22.7

3.9

28.4

4.8

Humira

1,765

462

2,227

(41.6)

(12.4)

(37.2)

(7.8)

(36.5)

Skyrizi

2,778

427

3,205

48.3

70.0

50.8

75.7

51.5

Rinvoq

1,170

444

1,614

45.9

44.0

45.3

51.6

47.4

Oncology

1,113

574

1,687

14.4

6.5

11.6

10.3

13.0

Imbruvicab

618

210

828

(8.9)

(8.4)

(8.8)

(8.4)

(8.8)

Venclexta

340

337

677

21.5

8.9

14.8

15.4

18.2

Elahere

139

—

139

n/m

n/m

n/m

n/m

n/m

Epkinlyc

16

27

43

13.4

>100.0

>100.0

>100.0

>100.0

Aesthetics

791

448

1,239

3.9

(6.4)

(0.1)

(1.6)

1.8

Botox Cosmetic

414

257

671

6.5

10.9

8.2

15.5

9.9

Juvederm Collection

105

153

258

(10.2)

(25.1)

(19.7)

(20.8)

(16.9)

Other Aesthetics

272

38

310

6.4

(10.0)

4.0

(2.0)

5.1

Neuroscience

2,088

275

2,363

14.9

21.2

15.6

25.1

16.0

Botox Therapeutic

708

140

848

13.1

14.6

13.4

20.7

14.4

Vraylar

873

2

875

16.5

49.3

16.6

51.9

16.6

Duodopa

24

87

111

(4.7)

(7.1)

(6.6)

(6.4)

(6.0)

Ubrelvy

261

8

269

13.6

>100.0

15.3

>100.0

15.3

Qulipta

168

8

176

28.3

>100.0

33.6

>100.0

33.6

Other Neuroscience

54

30

84

(4.1)

>100.0

36.4

>100.0

37.1

Eye Care

240

285

525

(22.9)

(3.5)

(13.5)

1.2

(11.2)

Ozurdex

33

86

119

(2.3)

(0.3)

(0.9)

2.5

1.1

Lumigan/Ganfort

58

58

116

>100.0

(7.0)

27.2

(2.7)

30.2

Alphagan/Combigan

26

36

62

(15.3)

(10.0)

(12.3)

(4.5)

(9.2)

Restasis

8

13

21

(92.5)

2.1

(82.2)

8.1

(81.5)

OtherEye Care

115

92

207

1.7

(2.0)

—

4.2

2.8

Other Key Products

710

164

874

(5.6)

(22.1)

(9.3)

(19.5)

(8.7)

Mavyret

147

155

302

(12.7)

(23.1)

(18.4)

(20.5)

(17.0)

Creon

338

—

338

10.6

n/m

10.6

n/m

10.6

Linzess/Constella

225

9

234

(19.2)

0.4

(18.6)

2.0

(18.6)

a

"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

b

Reflects profit sharing for Imbruvica international revenues.

c

EpkinlyU.S.revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.

n/m = not meaningful

AbbVie Inc.

Key Product Revenues

Nine Months EndedSeptember 30, 2024

(Unaudited)

% Change vs. 9M23

Net Revenues (in millions)

Reported

Operationala

U.S.

Int'l.

Total

U.S.

Int'l.

Total

Int'l.

Total

NET REVENUES

$31,295

$9,937

$41,232

1.7 %

7.5 %

3.0 %

12.2 %

4.1 %

Immunology

15,582

3,806

19,388

(2.4)

18.2

1.1

24.2

2.1

Humira

5,896

1,415

7,311

(37.4)

(15.8)

(34.1)

(10.8)

(33.3)

Skyrizi

6,774

1,166

7,940

45.8

61.8

47.9

66.6

48.5

Rinvoq

2,912

1,225

4,137

53.6

49.6

52.4

58.5

55.1

Oncology

3,117

1,747

4,864

11.1

9.2

10.4

12.7

11.7

Imbruvicab

1,823

676

2,499

(8.0)

(4.9)

(7.2)

(4.9)

(7.2)

Venclexta

921

1,007

1,928

13.6

13.4

13.5

19.7

16.8

Elaherec

331

—

331

n/m

n/m

n/m

n/m

n/m

Epkinlyd

42

64

106

>100.0

>100.0

>100.0

>100.0

>100.0

Aesthetics

2,430

1,448

3,878

2.7

(7.0)

(1.2)

(2.2)

0.7

Botox Cosmetic

1,253

780

2,033

2.9

4.5

3.5

9.1

5.3

Juvederm Collection

349

549

898

(4.1)

(19.3)

(14.0)

(14.6)

(10.9)

Other Aesthetics

828

119

947

5.6

(8.7)

3.5

(1.8)

4.5

Neuroscience

5,697

793

6,490

15.6

14.1

15.4

17.0

15.8

Botox Therapeutic

1,988

422

2,410

8.8

8.6

8.8

13.1

9.6

Vraylar

2,338

5

2,343

18.9

76.0

18.9

76.9

18.9

Duodopa

72

267

339

(3.3)

(4.4)

(4.1)

(4.0)

(3.8)

Ubrelvy

685

18

703

19.3

>100.0

20.9

>100.0

20.9

Qulipta

442

15

457

51.3

>100.0

55.5

>100.0

55.5

Other Neuroscience

172

66

238

(11.6)

>100.0

13.5

>100.0

14.1

Eye Care

706

890

1,596

(24.7)

(0.3)

(12.8)

3.8

(10.8)

Ozurdex

102

272

374

(4.4)

10.0

5.7

13.1

7.8

Lumigan/Ganfort

129

181

310

(9.5)

(8.7)

(9.0)

(5.9)

(7.4)

Alphagan/Combigan

54

116

170

(40.3)

(0.1)

(17.7)

6.9

(13.8)

Restasis

70

40

110

(73.4)

(7.4)

(64.2)

(2.2)

(63.5)

OtherEye Care

351

281

632

5.3

(2.4)

1.7

2.1

3.8

Other Key Products

2,146

590

2,736

(3.4)

(4.2)

(3.6)

(0.9)

(2.9)

Mavyret

458

562

1,020

(13.9)

(4.6)

(9.0)

(1.2)

(7.2)

Creon

995

—

995

11.5

n/m

11.5

n/m

11.5

Linzess/Constella

693

28

721

(13.2)

6.2

(12.6)

6.0

(12.6)

a

"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.

b

Reflects profit sharing for Imbruvica international revenues.

c

Reflects partial year Elahere revenue based on theFebruary 12, 2024close date of the ImmunoGen acquisition.

d

EpkinlyU.S.revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.

n/m = not meaningful

AbbVie Inc.

Consolidated Statements of Earnings

(Unaudited)

(in millions, except per share data)

Third Quarter

EndedSeptember 30

Nine Months

EndedSeptember 30

2024

2023

2024

2023

Net revenues

$ 14,460

$ 13,927

$ 41,232

$ 40,017

Cost of products sold

4,212

6,485

12,508

14,711

Selling, general and administrative

4,205

3,372

10,897

9,679

Research and development

2,130

1,723

6,017

5,748

Acquired IPR&D and milestones

82

66

1,183

496

Other operating income

—

—

—

(179)

Total operating costs and expenses

10,629

11,646

30,605

30,455

Operating earnings

3,831

2,281

10,627

9,562

Interest expense, net

591

398

1,550

1,306

Net foreign exchange loss (gain)

(3)

25

2

97

Other expense (income), net

1,159

(95)

3,090

3,121

Earnings before income tax expense

2,084

1,953

5,985

5,038

Income tax expense

520

172

1,676

989

Net earnings

1,564

1,781

4,309

4,049

Net earnings attributable to noncontrolling interest

3

3

9

8

Net earnings attributable toAbbVie Inc.

$ 1,561

$ 1,778

$ 4,300

$ 4,041

Diluted earnings per share attributable toAbbVie Inc.

$ 0.88

$ 1.00

$ 2.41

$ 2.26

Adjusted diluted earnings per sharea

$ 3.00

$ 2.95

$ 7.96

$ 8.32

Weighted-average diluted shares outstanding

1,772

1,771

1,772

1,772

a

Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)

1. Specified items impacted results as follows:

Quarter EndedSeptember 30, 2024

(in millions, except per share data)

Earnings

Diluted

Pre-tax

After-taxa

EPS

As reported (GAAP)

$ 2,084

$ 1,561

$ 0.88

Adjusted for specified items:

Intangible asset amortization

1,888

1,600

0.89

Acquisition and integration costs

307

283

0.16

Change in fair value of contingent consideration

1,356

1,321

0.75

Litigation matters

692

543

0.31

Other

30

19

0.01

As adjusted (non-GAAP)

$ 6,357

$ 5,327

$ 3.00

aRepresents net earnings attributable toAbbVie Inc.

Acquisition and integration costs primarily reflect costs related to theCerevel Therapeuticsacquisition. Litigation mattersprimarily include charges related to actual and potential settlements of litigation.

Reported GAAP earnings and adjusted non-GAAP earnings for the three months endedSeptember 30, 2024includedacquired IPR&D and milestone expense of $82 million on a pre-tax and $74 million on an after-tax basis, representingan unfavorable impact of$0.04to both diluted EPS and adjusted diluted EPS.

2. The impact of the specified items by line item was as follows:

Quarter EndedSeptember 30, 2024

(in millions)

Cost ofproductssold

SG&A

R&D

Otherexpense(income),net

As reported (GAAP)

$ 4,212

$ 4,205

$ 2,130

$ 1,159

Adjusted for specified items:

Intangible asset amortization

(1,888)

—

—

—

Acquisition and integration costs

(43)

(189)

(75)

—

Change in fair value of contingent consideration

—

—

—

(1,356)

Litigation matters

—

(692)

—

—

Other

(30)

2

—

(2)

As adjusted(non-GAAP)

$ 2,251

$ 3,326

$ 2,055

$ (199)

3. The adjusted tax rate for the third quarter of 2024 was 16.2 percent, as detailed below:

Quarter EndedSeptember 30, 2024

(dollars in millions)

Pre-taxearnings

Income taxes

Tax rate

As reported (GAAP)

$ 2,084

$ 520

25.0 %

Specified items

4,273

507

11.9 %

As adjusted(non-GAAP)

$ 6,357

$ 1,027

16.2 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)

1. Specified items impacted results as follows:

Quarter EndedSeptember 30, 2023

(in millions, except per share data)

Earnings

Diluted

Pre-tax

After-taxa

EPS

As reported (GAAP)

$ 1,953

$ 1,778

$ 1.00

Adjusted for specified items:

Intangible asset amortization

2,039

1,728

0.98

Intangible asset impairment

2,114

1,660

0.93

Acquisition and integration costs

60

54

0.03

Change in fair value of contingent consideration

8

8

—

Other

59

22

0.01

As adjusted (non-GAAP)

$ 6,233

$ 5,250

$ 2.95

aRepresents net earnings attributable toAbbVie Inc.

Intangible asset impairment reflects a partial impairment charge related to theU.S.Imbruvica intangible asset acquired aspart of the 2015 acquisition ofPharmacyclics, Inc.The intangible asset impairment charge was triggered by selection ofImbruvica for price negotiation as part of the IRA of 2022, which contributed to a significant decrease in the estimated futurecash flows for the product

Reported GAAP earnings and adjusted non-GAAP earnings for the three months endedSeptember 30, 2023includedacquired IPR&D and milestones expense of $66 million on a pre-tax and after-tax basis, representing an unfavorableimpact of$0.04to both diluted EPS and adjusted diluted EPS.

2. The impact of the specified items by line item was as follows:

Quarter EndedSeptember 30, 2023

(in millions)

Cost ofproductssold

SG&A

R&D

Otherexpense(income),net

As reported (GAAP)

$ 6,485

$ 3,372

$ 1,723

$ (95)

Adjusted for specified items:

Intangible asset amortization

(2,039)

—

—

—

Intangible asset impairment

(2,114)

—

—

—

Acquisition and integration costs

(18)

(40)

(2)

—

Change in fair value of contingent consideration

—

—

—

(8)

Other

(13)

(2)

(1)

(43)

As adjusted(non-GAAP)

$ 2,301

$ 3,330

$ 1,720

$ (146)

3. The adjusted tax rate for the third quarter of 2023 was 15.7 percent, as detailed below:

Quarter EndedSeptember 30, 2023

(dollars in millions)

Pre-taxearnings

Income taxes

Tax rate

As reported (GAAP)

$ 1,953

$ 172

8.8 %

Specified items

4,280

808

18.9 %

As adjusted(non-GAAP)

$ 6,233

$ 980

15.7 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)

1. Specified items impacted results as follows:

Nine Months EndedSeptember 30, 2024

(in millions, except per share data)

Earnings

Diluted

Pre-tax

After-taxa

EPS

As reported (GAAP)

$ 5,985

$ 4,300

$ 2.41

Adjusted for specified items:

Intangible asset amortization

5,726

4,854

2.73

Acquisition and integration costs

963

894

0.50

Change in fair value of contingent consideration

3,492

3,402

1.92

Litigation matters

737

585

0.33

Other

96

122

0.07

As adjusted (non-GAAP)

$ 16,999

$ 14,157

$ 7.96

aRepresents net earnings attributable toAbbVie Inc.

Acquisition and integration costs primarily reflect costs related to the ImmunoGen andCerevel Therapeuticsacquisitions.Litigation matters primarily include charges related to actual and potential settlements of litigation.

Reported GAAP earnings and adjusted non-GAAP earnings for the nine months endedSeptember 30, 2024included acquiredIPR&D and milestones expense of$1.2 billion on a pre-tax and$1.1 billion on an after-tax basis, representing an unfavorableimpact of$0.64to both diluted EPS and adjusted diluted EPS.

2. The impact of the specified items by line item was as follows:

Nine Months EndedSeptember 30, 2024

(in millions)

Cost ofproductssold

SG&A

R&D

Interestexpense,net

Otherexpense(income),net

As reported (GAAP)

$ 12,508

$ 10,897

$ 6,017

$ 1,550

$ 3,090

Adjusted for specified items:

Intangible asset amortization

(5,726)

—

—

—

—

Acquisition and integration costs

(201)

(504)

(234)

(24)

—

Change in fair value of contingent consideration

—

—

—

—

(3,492)

Litigation matters

—

(737)

—

—

—

Other

(87)

17

—

—

(26)

As adjusted(non-GAAP)

$ 6,494

$ 9,673

$ 5,783

$ 1,526

$ (428)

3. The adjusted tax rate for the first nine months of 2024 was 16.7 percent, as detailed below:

Nine Months EndedSeptember 30, 2024

(dollars in millions)

Pre-taxearnings

Income taxes

Tax rate

As reported (GAAP)

$ 5,985

$ 1,676

28.0 %

Specified items

11,014

1,157

10.5 %

As adjusted(non-GAAP)

$ 16,999

$ 2,833

16.7 %

AbbVie Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

(Unaudited)

1. Specified items impacted results as follows:

Nine Months EndedSeptember 30, 2023

(in millions, except per share data)

Earnings

Diluted

Pre-tax

After-taxa

EPS

As reported (GAAP)

$ 5,038

$ 4,041

$ 2.26

Adjusted for specified items:

Intangible asset amortization

6,057

5,101

2.87

Intangible asset impairment

2,824

2,289

1.29

Acquisition and integration costs

38

15

0.01

Change in fair value of contingent consideration

3,432

3,348

1.88

Other

75

16

0.01

As adjusted (non-GAAP)

$ 17,464

$ 14,810

$ 8.32

aRepresents net earnings attributable toAbbVie Inc.

Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gainof$169 millionrelated to the termination of a development liability associated with a previously divested product. Intangibleasset impairment primarily reflects a partial impairment charge of$2.1 billionrelated to theU.S.Imbruvica intangible assetacquired as part of the 2015 acquisition ofPharmacyclics, Inc.The intangible asset impairment was triggered by selection ofImbruvica for price negotiation as part of the IRA of 2022, which contributed to a significant decrease in the estimated futurecash flows for the product.

Reported GAAP earnings and adjusted non-GAAP earnings for the nine months endedSeptember 30, 2023included acquiredIPR&D and milestones expense of $496 million on a pre-tax and $477 million on an after-tax basis, representing an unfavorableimpact of$0.27to both diluted EPS and adjusted diluted EPS.

2. The impact of the specified items by line item was as follows:

Nine Months EndedSeptember 30, 2023

(in millions)

Cost ofproductssold

SG&A

R&D

Otheroperatingincome

Otherexpense(income),net

As reported (GAAP)

$ 14,711

$ 9,679

$ 5,748

$ (179)

$ 3,121

Adjusted for specified items:

Intangible asset amortization

(6,057)

—

—

—

—

Intangible asset impairment

(2,194)

—

(630)

—

—

Acquisition and integration costs

(66)

(134)

(7)

169

—

Change in fair value of contingent consideration

—

—

—

—

(3,432)

Other

(45)

(13)

(4)

10

(23)

As adjusted(non-GAAP)

$ 6,349

$ 9,532

$ 5,107

$ —

$ (334)

3. The adjusted tax rate for the first nine months of 2023 was 15.2 percent, as detailed below:

Nine Months EndedSeptember 30, 2023

(dollars in millions)

Pre-taxearnings

Income taxes

Tax rate

As reported (GAAP)

$ 5,038

$ 989

19.6 %

Specified items

12,426

1,657

13.3 %

As adjusted(non-GAAP)

$ 17,464

$ 2,646

15.2 %

AbbVie logo

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2024-financial-results-302290774.html

SOURCEAbbVie

Media: Gabby Tarbert, (224) 244-0111; Investors: Liz Shea, (847) 935-2211; Todd Bosse, (847) 936-1182; Jeffrey Byrne, (847) 938-2923

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com